Navigation Links
Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
Date:6/1/2011

HOBOKEN, N.J. and PHILADELPHIA, June 1, 2011 /PRNewswire/ -- Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin targeted ruthenium based anti-cancer compound. The intracellular targets of NKP-1339 include GRP78, a key regulator of mis-folded protein processing. In preclinical studies, in vivo and in vitro activity has been demonstrated against multiple tumor types, including those resistant to other anti-cancer agents.

The NKP-1339 Phase I trial is a dose-ascending trial and determines the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of NKP-1339. A total of 16 patients with metastatic solid tumors resistant to standard therapies have been treated to date at six different dose levels. NKP-1339 treatment has been generally well tolerated, with the most common drug related side effects of grade 1-2 fever and mild flu-like symptoms. MTD has not been reached and NKP-1339 dose escalation continues. Signs of anti-tumor activity (stable disease greater than or equal to four months; tumor regression) have been observed. A patient with a neuroendocrine tumor (NET) of the small intestine has been on NKP-1339 therapy for over 13 months with a continuing minor response. The patient remains on NKP-1339 therapy. Another patient with the metastatic gastrinoma NET exhibited six months stable disease, and two patients with metastatic non-small cell lung cancer exhibited four months stable disease.

The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Translational Genomics Institute, Arizona, and Dr. Howard Burris, Sarah Canon Research Institute, Tennessee. Reflecting on NKP-1339's novel mechanism of action, Dr. Von Hoff noted "Resistance to anti-cancer therapy remains a major challenge in treatment of patients with metastatic cancer. First-
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
3. Novel Device Shows Promise for Reducing HIV Among Men
4. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
5. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
6. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
7. MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
10. Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive ... world-renowned leader in the field of infertility, presents ... to embryonic screening. The research abstract, released during ... Reproductive Medicine (ASRM) meeting in Honolulu, ... and single gene defect (SGD) pre-implantation genetic diagnosis ...
(Date:10/22/2014)... SAN DIEGO , Oct. 22, 2014 ... II medical device received 510 (k) OTC clearance by ... the AVACEN 100 to be marketed over the Internet ... with arthritis; muscle spasms; and minor strains and sprains ... The AVACEN 100 (MSRP $2495) is a ...
(Date:10/22/2014)... Pa. , Oct. 22, 2014  With ... their animal health medications, a Global Pharmaceutical and ... Antares serialization technology and turnkey solution to protect ... - http://photos.prnewswire.com/prnh/20141021/153438 Photo ... product that was serialized and aggregated by the ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Breast cancer patients, their families and advocates expressed ... decision to remove the anti-cancer drug Avastin from the ... cancer. Terry Kalley, founder of the ... decision, saying, "While this vote is highly disappointing, it ...
... N.Y., Nov. 18, 2011  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... (FDA) has approved EYLEA (aflibercept) Injection, known in ... patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a ... for the first 12 weeks, followed by 2 mg every ...
Cached Medicine Technology:Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 2Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 3Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 4Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 5Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 6Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 7Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 8
(Date:10/22/2014)... RESTON, Va. (PRWEB) October 22, 2014 ... Healthcare Innovation , which is dedicated to distribute ... efficiency of healthcare delivery worldwide announced the development ... in which patients expect when receiving healthcare. These ... definition for patient-centered care: “providing care that is ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... By Maureen Salamon ... -- Black women undergoing in vitro fertilization (IVF) are only ... using the popular assisted reproduction technique, new research indicates, and ... In the study, about 31 percent of white patients ... black patients. Analyzing more than 4,000 IVF cycles over ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... was chosen by Ethicon Endo-Surgery (a Johnson & ... Band, to be among the first bariatric surgeons ... with the next generation of its distinctive surgical ... Personalized Banding Solution is gaining a reputation as ...
... Feb. 2 Today, AARP testified at New York ... issues that impact the health care and quality of ... drug access and affordability, health care access, and home ... New Yorkers staying healthy and having access to the ...
... Now Available at Sunrise Communities and Online -MCLEAN, Va. ... SRZ ) now offers a new informational guide to ... senior care in today,s challenging economy. The guide, ... is available at Sunrise communities nationwide and also online ...
... The American Dietetic Association will pursue a broad agenda ... Congress that a primary goal of new legislation should be ... should improve as a result of our health policy choices," ... needs to rise as a national priority, as it ties ...
... Server Enables Enterprises to Capture and Automate Faxes to Enhance Productivity ... ... February 2, 2009 -- FaxBack® , the high-density VoIP fax ... Fax Machine Integration Server , an easy-to-install plug-in that turns ...
... substance abuse, psychiatric woes rank low as risk factor, ... Mental illness alone is not a predictor of future ... or dependence does increase the risk, according to U.S. ... , People who have a severe mental illness but ...
Cached Medicine News:Health News:Dallas – Fort Worth Bariatric Surgeon Dr. David Kim One of Few in America Selected to Perform New Weight Loss Surgery Procedure 2Health News:Dallas – Fort Worth Bariatric Surgeon Dr. David Kim One of Few in America Selected to Perform New Weight Loss Surgery Procedure 3Health News:Dallas – Fort Worth Bariatric Surgeon Dr. David Kim One of Few in America Selected to Perform New Weight Loss Surgery Procedure 4Health News:AARP Urges Governor to Use Budget to Maintain Quality of Life For Aging New Yorkers 2Health News:AARP Urges Governor to Use Budget to Maintain Quality of Life For Aging New Yorkers 3Health News:Sunrise Senior Living Helps Families Explore Senior Care Financing Options with New Guide 2Health News:American Dietetic Association Announces Agenda for Health Reform 2Health News:FaxBack Enables Fax Machine Integration With Document Management Systems 2Health News:FaxBack Enables Fax Machine Integration With Document Management Systems 3Health News:Mental Illness Doesn't Predict Violent Behavior 2
... Stellate Harmonie workstation is a medical device ... high quality video capability, and archiving demands ... review functions A framework that helps organize ... of data A centralized database and powerful ...
...
These are superior quality electrodes, fabricated from a single length of polyurethane tubing for strength and uniform smoothness. They are furnished with a specially-designed rigid stylet to facilit...
Integra Epilepsy grid electrodes are thin and flexible for easier placement and to conform to the curvature of the cortical surface. Lead tunneling is done using a 14-gauge tunneling needle (ET-2)....
Medicine Products: